John Theurer Cancer Center Research at the 2012 ASH Annual Meeting
Download File
John Theurer Cancer Center to Present 37 Studies at the 2012 American Society of Hematology Annual Meeting
Nearly One-Third of the Studies are Invited for Oral Presentation at this Premier Hematology Research Conference
John Theurer Cancer Center is proud to have 37 presentations of new research and analysis selected by the American Society of Hematology (ASH) as some of “the best new scientific research in all areas of hematology,” according to ASH officials. The conference will be held in Atlanta from December 8-11, 2012
John Theurer Cancer Center's Research at the 2012 ASH Annual Meeting
Nearly one-third of John Thuerer Cancer Center’s 37 presentations showcased have been considered exceptionally significant and will be presented orally, including Phase I and Phase II studies, multi-center, international trials in collaboration with leading cancer institutions such as the National Cancer Institute, Dana-Farber Cancer Institute, and MD Anderson.
Remaining at the forefront of blood cancer research, John Theurer Cancer Center physicians are lead or senior author in 15 studies: Dr. Goy; Michele Donato, M.D., collection facility medical director, blood and marrow transplantation; Tatyana Feldman, M.D., lymphoma oncologist; Stuart Goldberg, M.D., chief, leukemia; Robert Korngold, Ph.D., chief, research; Anthony Mato, M.D., director, chronic lymphocytic leukemia; Scott Rowley, M.D., chief, blood and marrow transplantation; David Siegel, M.D., Ph.D., chief, multiple myeloma.
Research Highlights
Among the studies to be presented will be a Phase II multicenter trial, led by John Theurer Cancer Center researchers, of immunomodulatory drug lenalidomide for patients with relapsed or progressed mantle cell lymphoma; Phase II clinical trial conducted to gather additional safety and efficacy data on longer-term treatment with selective proteasome inhibitor carfilzomib (Kyprolis™). Carfilzomib was approved this summer for treating refractory myeloma, based on data from multicenter trials led by John Theurer Cancer Center researchers.
Other research of interest includes a study of long-term allogeneic bone marrow transplantation outcomes for patients with aggressive lymphomas; a multi-year study to determine if zolendronic acid can prevent the common side effect of osteoporosis after hematopoetic cell transplantation; and a multicenter study of virus-specific T-cells to prevent or treat serious infections in stem cell transplant patients.
Find JTCC at ASH - Booth 3413
You can download a PDF of all the JTCC abstracts being presented at ASH (see box at top right-hand corner of the website). If you are attending the ASH annual meeting, we encourage you to attend these presentations or visit us at Booth 3413.
Media Requests for JTCC Experts
If you would like to interview our experts prior to or at the ASH annual meeting, please contact Amy Leahing at 305-458-0599 or aleahing@p4strategy.com
| Abstract #/Title | JTCC Author* | Oral/Poster | Date | Time | Location |
|---|---|---|---|---|---|
| 59 A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL) | Goy | Oral Session: 624. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Novel Agents and Targeted Therapies | 9-Dec-12 | 1:00PM | Sidney Marcus Auditorium, Level 4, Building A (Georgia World Congress Center) |
| 203 A Phase 1b Dose-Escalation Study of Split-Dose Oprozomib (ONX0912) in Patients with Hematologic Malignancies | Siegel | Oral Session: 653. Myeloma - Therapy, excluding Transplantation I | 9-Dec-12 | 5:30PM | Thomas Murphy Ballroom 2-3, Level 5, Building B (Georgia World Congress Center) |
| 331 Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression | Siegel | Oral Session: 653. Myeloma - Therapy, excluding Transplantation: Treatment options for newly diagnosed myeloma patients | 10-Dec-12 | 7:00AM | Thomas Murphy Ballroom 2-3, Level 5, Building B (Georgia World Congress Center) |
| 450 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis | Siegel | Oral Session: 653. Myeloma - Therapy, excluding Transplantation II | 10-Dec-12 | 11:45AM | Thomas Murphy Ballroom 2-3, Level 5, Building B (Georgia World Congress Center) |
| 457 Multicenter Study of “off-the-Shelf” Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT) | Rowley | Oral Session: 721. Clinical Allogeneic Transplantation - Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Infectious Disease Challenges | 10-Dec-12 | 10:30AM | C101, Level 1, Building C (Georgia World Congress Center) |
| 471 Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT | Rowley, Donato, Goy, Pecora, Carini, Feldman | Oral Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Strategies to Prevent or Treat Relapse After Transplantation | 10-Dec-12 | 11:00 AM | B312-B313a (Georgia World Congress Center) |
| 686 The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study | Goy | Oral Session: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Aggressive B-Cell Lymphoma | 10-Dec-12 | 4:45 PM | Sidney Marcus Auditorium, Level 4, Building A (Georgia World Congress Center) |
| 727 MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma | Siegel |
Oral session: 653. Myeloma - Therapy, excluding Transplantation III |
10-Dec-12 | 4:30 PM | Thomas Murphy Ballroom 2-3, Level 5, Building B (Georgia World Congress Center) |
| 738 Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome – Updated Results of a Treatment IND (T-IND) Expanded Access Protocol | Gillio | Session: 721. Clinical Allogeneic Transplantation - Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Toxicities | 10-Dec-12 | 5:45 PM | C101, Level 1, Building C (Georgia World Congress Center) |
| 895 SOX11 Directly Represses Wnt/β-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment | Suh, Goy | Oral Session: 622. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Highly Aggressive Lymphomas | 11-Dec-12 | 7:30 AM | B313b-B314, Level 3, Building B (Georgia World Congress Center) |
| 904 Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up | Goy | Oral Session: 624. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Optimizing Current Treatment Strategies | 11-Dec-12 | 8:15 AM | B405-B407, Level 4, Building B (Georgia World Congress Center) |
| 905 Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study | Goy | Oral Session: 624. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Optimizing Current Treatment Strategies | 11-Dec-12 | 8:30 AM | B405-B407, Level 4, Building B (Georgia World Congress Center) |
| 1579 Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome | Anthony R Mato, MD, K. Stephen Suh, PhD, Yvonne Remache, BA, BSN, Tania Zielonka, RD, Kathryn Waksmundzki, BS, Ewelina A Protomastro, BA1, Susan Stives, APN, Tatyana Feldman, MD1, Pritish K. Bhattacharyya, MD, Xiao Yang, M.D. Ph.D, Kar Fai Chow, MD, Alex Campaiola, BSN, Andrew L Pecora, MD and Andre Goy, MD1 | Session: 622. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Poster I | 8-Dec-12 | 5:30-7:30 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 1623 A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma | Goy | Pral and poster Session: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Poster I | 8-Dec-12 | 5:30-7:30 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 1685 Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey | Goldberg | Oral and Poster Session: 632. Chronic Myeloid Leukemia - Therapy: Poster I | 8-Dec-12 | 5:30-7:30 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 1936 Decitabine Plus Mini Fludarabine and Busulfan Yields Durable Engraftment with Low Relapse Rates in Elderly or Medically Infirm Patients with Myeloid Malignancies | Melissa F Baker, APN, Scott D Rowley, MD, Stuart L. Goldberg, MD, Anthony R Mato, MD, Andrew L Pecora, MD, David H. Vesole, MD, PhD, Phyllis McKiernan, APN, Andre Goy, MD and Michele L. Donato, MD | Oral and Poster Session: 721. Clinical Allogeneic Transplantation - Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Poster I | 8-Dec-12 | 5:30-7:30 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 1965 Intermittent Zolendronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT) | Vesole | Oral and Poster Session: 723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Poster I | 8-Dec-12 | 5:30-7:30 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 2630 Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles | Goldberg | Oral and Poster Session: 615. Acute Myeloid Leukemia - Therapy, excluding Transplantation: Poster II | 9-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 2728 Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort | Feldman, Goy | Oral and Poster Session: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Poster II | 9-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 2751 Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib | Goy | Program: Oral and Poster Abstracts Session: 624. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II | 9-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 2962 A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials | Siegel, Bilotti | Oral and Poster Session: 653. Myeloma - Therapy, excluding Transplantation: Poster II | 9-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 3041 Evaluation of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Non-Stem Cell Transplant (non-SCT) Chemotherapy Patients (pts): Results From the Treatment IND (T-IND) Expanded Access Protocol and the Compassionate Use Program (CUP) | Gillio | Session: 721. Clinical Allogeneic Transplantation - Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Poster II | 9-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 3054 Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation | Korngold | Oral and Poster Session: 722. Clinical Allogeneic Transplantation - Acute and Chronic GVHD, Immune Reconstitution: Poster II | 9-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 3104 A Phase I/II Study of Escalating Doses of Thalidomide (Thal) in Conjunction with Bortezomib (Vel) and High Dose Melphalan (Mel) As A Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Patients with Advanced Multiple Myeloma (MM) | Sung H Hong, David S Siegel, MD, PhD., Michele L Donato, MD, David H. Vesole, MD, PhD, Andrew L Pecora, MD, Joshua R. Richter, MD, Emily Brown, BSN, RN, CHPN*, Kathryn Buttner, BSN, RN, OCN, Marie DelFavero, BSN, RN, CCRP, Daniel Kim, Andrea Ortega, BA, CCRP and Scott D Rowley, MD | Oral and Poster Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster II | 9-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 3120 Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center | Anthony R Mato, MD, Kathryn Waksmundzki, BS, Tania Zielonka, RD, Ewelina A Protomastro, BA, Theresa Amatucci, BS, Maria Rosario, Stuart L. Goldberg, MD, Tatyana Feldman, MD1, Scott D Rowley, MD, Michele L. Donato, MD1, Mary Timberg, RN, MSN, OCN, NP-C, Melissa F Baker, APN, Pam Sutherland, MSN, CRN, Phyllis McKiernan, MSN, CRN, Andrew L Pecora, MD1* and Andre Goy, MD | Oral and Poster Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster II | 9-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 3638 Baseline Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) Expression in Circulating CD15+/CD30+ Cells Correlate with Very Poor Outcome in Hodgkin Lymphoma | Goy, Mato, Feldman, Pecora, Suh | Oral and Poster Session: 621. Hodgkin Lymphoma - Biology, excluding Therapy: Poster III | 10-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 3658 Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients | Anthony R Mato, MD1, Ewelina A Protomastro, BA, Tania Zielonka, RD, Tatyana Feldman, MD, Scott D Rowley, MD, Michele L Donato, MD, Andrew L Pecora, MD, Pritish K. Bhattacharyya, MD2, Mary Timberg, RN, MSN, OCN, NP-C, Susan Stives, APN*, Gabriella Gadaleta, RN, APN-C, Coleen Bejot, MSN, NP-C and Andre Goy, MD | Oral and Poster Session: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Poster III | 10-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 3659 Outcomes in Adolescents and Young Adults with Hodgkin Lymphoma Treated with and without Radiation Therapy On CCG 5942: A Report From the Children’s Oncology Group | Appel | Oral and Poster Session: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Poster III | 10-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 3678 Phase 1b Study of TRU-016, an Anti-CD37 SMIPTM Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma | Feldman, Mato, Goy | Oral and Poster Session: 624. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III | 10-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 3710 Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant | Tatyana Feldman, MD, Anthony R Mato, MD, Michele L. Donato, MD, Scott D Rowley, MD, Stuart L. Goldberg, MD, Carolanne Carini, RN, Marisa Valentinetti, RN, Judith Smith, RN, Gabriella Gadaleta, RN, APN-C, Coleen Bejot, MSN, NP-C, Susan Stives, APN, Mary Timberg, RN, MSN, OCN, NP-C, Ewelina A Protomastro, BA*, Joshua R. Richter, MD, David H. Vesole, MD, PhD, Andrew L Pecora, MD, David S. Siegel, MD, PhD and Andre Goy, MD | Oral and Poster Session: 624. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III | 10-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 4036 A Phase 1b Study of 30-Minute Infusion Carfilzomib 20/45 and 20/56 Mg/m2 Plus 40 Mg Weekly Dexamethasone in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma | Siegel | Oral and Poster Session: 653. Myeloma - Therapy, excluding Transplantation: Poster III | 10-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 4038 MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin’s Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study | Siegel |
Oral and Poster Session: 653. Myeloma - Therapy, excluding Transplantation: Poster III |
10-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 4053 Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT) | Siegel | Oral and Poster Program: Oral and Poster Abstracts Session: 653. Myeloma - Therapy, excluding Transplantation: Poster III | 10-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 4070 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure | Siegel | Oral and Poster Session: 653. Myeloma - Therapy, excluding Transplantation: Poster III | 10-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 4072 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes | Siegel | Oral and Poster Session: 653. Myeloma - Therapy, excluding Transplantation: Poster III | 10-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 4106 Use of the Immunoproteasome Subunit LMP7 Inhibitor to Ameliorate Gvhd in an MHC-Matched miHA-Disparate Murine Model | Korngold | Oral and Poster Session: 702. Experimental Transplantation - Immune Function, GVHD and Graft-versus-Tumor Effects: Poster III | 10-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
| 4269 Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population | Anthony R Mato, MD, Andre Goy, MD, Kathryn Waksmundzki, BS, Tatyana Feldman, MD, Tania Zielonka, RD, Ewelina A Protomastro, BA, Coleen Bejot, MSN, NP-C, Gabriella Gadaleta, RN, APN-C, Scott D Rowley, MD1, Michele L Donato, MD, Andrew L Pecora, MD, Katherine Facchin, RN | Session: 901. Health Services and Outcomes Research: Poster III | 10-Dec-12 | 6:00-8:00 PM | Hall B1-B2, Level 1, Building B (Georgia World Congress Center) |
* Authors in bold are lead authors, senior authors or moderating a discussion